# A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

> **NCT01327053** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 230 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** LDE225

## Key facts

- **NCT ID:** NCT01327053
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-29
- **Primary completion:** 2013-06-28
- **Final completion:** 2018-06-29
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327053, "A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01327053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*